Molecularly Engineered PEG-TRAP Conjugates for Platelet Activation and Accelerated Hemostasis

01 February 2022, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Synthetic peptide conjugates that can molecularly target and activate blood platelets are designed for hemostasis applications. An engineered thrombin receptor-activating peptide (TRAP-Cys, SFLLRNPNC) is covalently attached to cell-compatible 8-arm poly (ethylene glycol) maleimides via Michael addition. It is proved that the ability of TRAP to activate platelets is retained in the conjugated form by means of thromboelastometry, platelet aggregation assay and flow cytometry. A 0.5 % PEG-TRAP solution can efficiently activate platelets and shorten the clotting time to ~45 %.

Keywords

Polymer-peptide conjugates
platelet activation
thrombin receptor-activating peptide (TRAP)
hemostasis
blood coagulation

Supplementary materials

Title
Description
Actions
Title
Supporting Information
Description
Methods Supporting Figures
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.